Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity

International Journal of Laboratory Hematology

Volumn 30, Issue 2, 2008, Pages 173-174

  Whittle, A M ^a   Ali, S ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ITRACONAZOLE; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ASPERGILLOSIS; CANCER CHEMOTHERAPY; DRUG CHOICE; HUMAN; LETTER; MULTIPLE ORGAN FAILURE; MYCOSIS; NERVE PARALYSIS; NEUROTOXICITY; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT LARYNGEAL NERVE PALSY;

ADULT; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; ITRACONAZOLE; MYCOSES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; TRIAZOLES;

EID: 40549102818     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00918.x     Document Type: Letter

References (10)

1. Bermudez M., Fuster J.L., Llinares E., Galera A. Gonzalez C. (2005) Itraconazole related increased vincristine neurotoxicity: case report and review of literature. Journal of Pediatric Hematology and Oncology 27, 389 392.
2. Bohme A., Ganser A. Hoelzer D. (1995) Aggravation of vincristine-induced neurotoxicity by Itraconazole in the treatment of adult ALL. Annals of Hematology 71, 311 312.
3. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M. Lode H. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clinical Infectious Diseases 34, 563 571.
4. Gillies J., Hung K.A., Fitzsimons E. Soutar R. (1998) Severe vincristine toxicity in combination with itraconazole. Clinical and Laboratory Haematology 20, 123 124.
5. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., Kern W.V., Marr K.A., Ribaud P., Lortholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P., Durand C., Caillot D., Thiel E., Chandrasekar P.H., Hodges M.R., Schlamm H.T., Troke P.F. de Pauw B. (2002) Voriconazole versus Amphotericin B for primary therapy of invasive Aspergillosis. New England Journal of Medicine 347, 408 415.
6. Jeu L., Piacenti F.J., Lyakhovetskiy A.G. Fung H.B. (2003) Voriconazole Clinical Therapeutics 25, 1321 1381.
7. Niwa T., Shiraga T. Takagi A. (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19 and CYP3A4 activities in human liver microsomes. Biological and Pharmaceutical Bulletin 28, 1805 1808.
8. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., DuPont B., de la Torre-Cisneros J., Just-Nubling G., Schlamm H.T., Lutsar I., Espinel-Ingroff A. Johnson E. (2003) Voriconazole treatment for less-common, emerging or refractory fungal infections. Clinical Infectious Diseases 36, 1122 1130.
9. Rowe J.M., Buck G., Burnett A.K., Chopra R., Wiernik P., Richards S.M., Lazarus H.M., Franklin I.M., Litzow M.R., Ciobanu N., Grant Prentice H., Durrant J., Tallman M.S. Goldstone A.H. (2005) Induction therapy for adults with acute lymphoblastic leukaemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106, 3760 3767.
10. Wingard J.R. Leather H. (2004) A New Era of Antifungal Therapy. British Journal of Bone Marrow Transplant 10, 73 90.